Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Recruiting

Phase 2

Levonorgestrel & MeloxicamOral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Sponsor:

InnovaGyn, Inc.

Code:

NCT05695352

Conditions

Pregnancy Prevention

Eligibility Criteria

Sex: Female

Age: 18 - 40

Healthy Volunteers: Accepted

Interventions

Levonorgestrel 1.5mg

Meloxicam 15 mg

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by InnovaGyn, Inc. on 2024-03-12.